NASDAQ:ABMD - ABIOMED Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$423.48 -2.51 (-0.59 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$425.99
Today's Range$422.32 - $429.78
52-Week Range$141.56 - $450.93
Volume712,600 shs
Average Volume632,729 shs
Market Capitalization$19.27 billion
P/E Ratio173.87
Dividend YieldN/A
Beta0.18
ABIOMED logoABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400

Debt

Debt-to-Equity RatioN/A
Current Ratio5.84
Quick Ratio5.24

Price-To-Earnings

Trailing P/E Ratio173.87
Forward P/E Ratio120.99
P/E Growth4.57

Sales & Book Value

Annual Sales$593.75 million
Price / Sales31.84
Cash Flow$2.7297 per share
Price / Cash155.14
Book Value$15.57 per share
Price / Book27.20

Profitability

EPS (Most Recent Fiscal Year)$2.45
Net Income$112.17 million
Net Margins18.89%
Return on Equity17.58%
Return on Assets15.37%

Miscellaneous

Employees1,143
Outstanding Shares44,640,000
Market Cap$19,265.18

ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings data on Thursday, May, 3rd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.16. The medical equipment provider had revenue of $174.44 million for the quarter, compared to the consensus estimate of $164.30 million. ABIOMED had a net margin of 18.89% and a return on equity of 17.58%. ABIOMED's quarterly revenue was up 39.9% on a year-over-year basis. During the same quarter last year, the company posted $0.33 earnings per share. View ABIOMED's Earnings History.

When is ABIOMED's next earnings date?

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for ABIOMED.

What price target have analysts set for ABMD?

8 brokerages have issued 12 month target prices for ABIOMED's shares. Their predictions range from $280.00 to $480.00. On average, they anticipate ABIOMED's share price to reach $363.1429 in the next year. This suggests that the stock has a possible downside of 14.2%. View Analyst Ratings for ABIOMED.

What is the consensus analysts' recommendation for ABIOMED?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of ABIOMED's key competitors?

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 51)
  • Dr. David M. Weber Ph.D., Chief Operating Officer (Age 57)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
  • Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
  • Mr. Todd A. Trapp, CFO & VP (Age 47)

Has ABIOMED been receiving favorable news coverage?

Media headlines about ABMD stock have trended somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ABIOMED earned a coverage optimism score of 0.11 on Accern's scale. They also gave headlines about the medical equipment provider an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are ABIOMED's major shareholders?

ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (4.72%), Fred Alger Management Inc. (0.86%), Scout Investments Inc. (0.76%), Chicago Capital LLC (0.14%), Rhenman & Partners Asset Management AB (0.14%) and Nisa Investment Advisors LLC (0.12%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Which major investors are selling ABIOMED stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Scout Investments Inc., Dorsey Wright & Associates, Municipal Employees Retirement System of Michigan, Louisiana State Employees Retirement System, Handelsbanken Fonder AB, Chicago Capital LLC and Fred Alger Management Inc.. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Insider Buying and Selling for ABIOMED.

Which major investors are buying ABIOMED stock?

ABMD stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Rhenman & Partners Asset Management AB, Nisa Investment Advisors LLC, Bank of Montreal Can, Pendal Group Ltd, Gulf International Bank UK Ltd, Fjarde AP Fonden Fourth Swedish National Pension Fund and NN Investment Partners Holdings N.V.. View Insider Buying and Selling for ABIOMED.

How do I buy shares of ABIOMED?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABMD stock can currently be purchased for approximately $423.48.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $19.27 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]


MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  353 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  629
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.